Shots:

• The approval is based on the study assessing Triferic in adult patients with hemodialysis-dependent chronic kidney disease and has resulted in steady and consistent bioavailable iron to replace the iron that is lost at every dialysis treatment and hemoglobin is maintained
• The company will launch Evaluation Programs for evaluating Triferic and with expected launch in Q3’20
• Triferic AVNU (ferric pyrophosphate citrate) is a IV formulation of Triferic and a novel treatment for iron replacement and maintenance of hemoglobin in hemodialysis patients

Click here ­to­ read full press release/ article | Ref: Rockwell | Image: Rockwell